{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:27:46Z","timestamp":1786652866797,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharm Bioall Sci"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0975-7406.154429","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T14:33:42Z","timestamp":1427898822000},"page":"103","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological evaluation of novel 5-HT\n                    <sub>3<\/sub>\n                    receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery"],"prefix":"10.4103","volume":"7","author":[{"given":"Deepali","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devadoss","family":"Thangaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshwant","family":"Kurhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0975-7406.154429-1","first-page":"203","volume-title":"Serotonergic modulation of the limbic system","author":"Hensler","year":"2006","journal-title":"Neurosci Biobehav Rev"},{"key":"key-10.4103\/0975-7406.154429-2","first-page":"357","volume-title":"Involvement of serotonin in depression: Evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter","author":"Stockmeier","year":"2003","journal-title":"J Psychiatr Res"},{"key":"key-10.4103\/0975-7406.154429-3","first-page":"455","volume-title":"The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target?","author":"Rajkumar","year":"2010","journal-title":"J Psychopharmacol"},{"key":"key-10.4103\/0975-7406.154429-4","first-page":"381","volume-title":"Research in anxiety disorders: From the bench to the bedside","author":"Garner","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"key-10.4103\/0975-7406.154429-5","first-page":"1401","volume-title":"Ultrastructure of the 5-hydroxytryptamine3 receptor","author":"Boess","year":"1995","journal-title":"J Neurochem"},{"key":"key-10.4103\/0975-7406.154429-6","first-page":"943","volume-title":"Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy","author":"Hammer","year":"2010","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/0975-7406.154429-7","doi-asserted-by":"crossref","unstructured":"Rodgers RJ, Cutler MG, Jackson JE. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze. Pharmacol Biochem Behav 1997;56:295-303.","DOI":"10.1016\/S0091-3057(96)00242-0"},{"key":"key-10.4103\/0975-7406.154429-8","first-page":"20","volume-title":"The non-antiemetic uses of serotonin 5-HT3 receptor antagonists.Clinical pharmacology and therapeutic applications","author":"Greenshaw","year":"1997","journal-title":"Drugs"},{"key":"key-10.4103\/0975-7406.154429-9","first-page":"677","volume-title":"Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs","author":"Rex","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-10","first-page":"362","volume-title":"Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test","author":"Bravo","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-11","first-page":"257","volume-title":"BRL 46470A: A highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties","author":"Blackburn","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/0975-7406.154429-12","first-page":"302","volume-title":"Zacopride: Anxiolytic profile in rodent and primate models of anxiety","author":"Costall","year":"1988","journal-title":"J Pharm Pharmacol"},{"key":"key-10.4103\/0975-7406.154429-13","first-page":"571","volume-title":"Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT (3) receptor antagonist, in the mouse elevated plus-maze","author":"Zhang","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-14","first-page":"77","volume-title":"5-HT (3) receptor antagonists and anxiety; a preclinical and clinical review","author":"Olivier","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"key-10.4103\/0975-7406.154429-15","first-page":"18","volume-title":"5HT (3) antagonism abolishes the emotion potentiated startle effect in humans","author":"Harmer","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/0975-7406.154429-16","first-page":"129","volume-title":"A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder","author":"Lecrubier","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/0975-7406.154429-17","first-page":"140","volume-title":"Efficacy of ondansetron in the treatment of generalized anxiety disorder","author":"Freeman","year":"1997","journal-title":"Depress Anxiety"},{"key":"key-10.4103\/0975-7406.154429-18","first-page":"321","volume-title":"Ethologically-based animal models of anxiety disorders","author":"Lister","year":"1990","journal-title":"Pharmacol Ther"},{"key":"key-10.4103\/0975-7406.154429-19","first-page":"167","volume-title":"Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines","author":"Crawley","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-20","first-page":"212","volume-title":"Action of caffeine on the spontaneous motility of the mouse","author":"Boissier","year":"1965","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"key-10.4103\/0975-7406.154429-21","first-page":"299","volume-title":"The olfactory bulbectomized rat as a model of depression: An update","author":"Kelly","year":"1997","journal-title":"Pharmacol Ther"},{"key":"key-10.4103\/0975-7406.154429-22","first-page":"32","volume-title":"1-(m-Chlorophenyl) piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT (2A) receptors: Proposal of a modified rodent antidepressant assay","author":"Rajkumar","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/0975-7406.154429-23","first-page":"215","volume-title":"Assessing the neuronal serotonergic target-based antidepressant stratagem: Impact of in vivo interaction studies and knockout models","author":"Rajkumar","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"key-10.4103\/0975-7406.154429-24","first-page":"619","volume-title":"Anti-depressant-like activity of a novel serotonin type-3 (5-HT3) receptor antagonist in rodent models of depression","author":"Gupta","year":"2011","journal-title":"Indian J Exp Biol"},{"key":"key-10.4103\/0975-7406.154429-25","first-page":"277","volume-title":"pAx and competitive drug antagonism","author":"Schild","year":"1949","journal-title":"Br J Pharmacol Chemother"},{"key":"key-10.4103\/0975-7406.154429-26","first-page":"327","volume-title":"Behavioral despair in mice: A primary screening test for antidepressants","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"key-10.4103\/0975-7406.154429-27","first-page":"3","volume-title":"Anxiolytic effect of baicalin in mice; anxiolytic effect of baicalin in mice","author":"Wei","year":"2006","journal-title":"Asian J Tradit Med"},{"key":"key-10.4103\/0975-7406.154429-28","first-page":"97","volume-title":"Desipramine blocks alcohol-induced anxiety- and depressive-like behaviors in two rat strains","author":"Getachew","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-29","first-page":"21","volume-title":"A review of the validity and variability of the elevated plus-maze as an animal model of anxiety","author":"Hogg","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-30","first-page":"739","volume-title":"A fully automated light\/dark apparatus useful for comparing anxiolytic agents","author":"Young","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-31","first-page":"739","volume-title":"Differences in anxiety-related behavior and response to diazepam in BALB\/cByJ and C57BL\/6J strains of mice","author":"Lepicard","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"key-10.4103\/0975-7406.154429-32","first-page":"21","volume-title":"Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and\/or anxiolytic state in mice","author":"Takeda","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/0975-7406.154429-33","first-page":"1","volume-title":"Buspirone: Review of its pharmacology and current perspectives on its mechanism of action","author":"Eison","year":"1986","journal-title":"Am J Med"}],"container-title":["Journal of Pharmacy And Bioallied Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:27:27Z","timestamp":1786649247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0975-7406.154429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"alternative-id":["154429"],"URL":"https:\/\/doi.org\/10.4103\/0975-7406.154429","relation":{},"ISSN":["0975-7406"],"issn-type":[{"value":"0975-7406","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}